OBJECTIVE: To compare the effects on back pain of teriparatide versus alendronate, we analyzed the reporting of back pain in a head to head comparator trial and a followup study. METHODS: In the comparator trial, women were randomized to receive either daily self-injected teriparatide 40 microg plus an oral placebo (n = 73), or daily oral alendronate 10 mg plus self-injected placebo (n = 73). Treatment was for a median 14 months. After completion of the comparator trial, 72% of these patients enrolled in a nontreatment followup study. Adverse events were recorded at each comparator trial visit and followup study visit, and the incidence of new or worsening back pain in each group was compared. RESULTS: During the comparator trial, compared with women randomized to alendronate 10 mg, women randomized to teriparatide 40 microg had reduced risk for any back pain (relative risk 0.27, 95% CI 0.09-0.82) and moderate or severe back pain (relative risk 0.19, 95% CI 0.04-0.86). The differences in the reporting of back pain between the teriparatide treated women and the alendronate treated women were sustained during an interval including the comparator trial plus 18 additional months. During an interval including the comparator trial plus 30 additional months, teriparatide treated patients had numerically fewer occurrences of back pain and moderate or severe back pain. CONCLUSION: Compared with women randomized to alendronate 10 mg, women randomized to teriparatide 40 microg had reduced risk of back pain during the trial and 2.5 years of followup.
RCT Entities:
OBJECTIVE: To compare the effects on back pain of teriparatide versus alendronate, we analyzed the reporting of back pain in a head to head comparator trial and a followup study. METHODS: In the comparator trial, women were randomized to receive either daily self-injected teriparatide 40 microg plus an oral placebo (n = 73), or daily oral alendronate 10 mg plus self-injected placebo (n = 73). Treatment was for a median 14 months. After completion of the comparator trial, 72% of these patients enrolled in a nontreatment followup study. Adverse events were recorded at each comparator trial visit and followup study visit, and the incidence of new or worsening back pain in each group was compared. RESULTS: During the comparator trial, compared with women randomized to alendronate 10 mg, women randomized to teriparatide 40 microg had reduced risk for any back pain (relative risk 0.27, 95% CI 0.09-0.82) and moderate or severe back pain (relative risk 0.19, 95% CI 0.04-0.86). The differences in the reporting of back pain between the teriparatide treated women and the alendronate treated women were sustained during an interval including the comparator trial plus 18 additional months. During an interval including the comparator trial plus 30 additional months, teriparatide treated patients had numerically fewer occurrences of back pain and moderate or severe back pain. CONCLUSION: Compared with women randomized to alendronate 10 mg, women randomized to teriparatide 40 microg had reduced risk of back pain during the trial and 2.5 years of followup.
Authors: Ann Cranney; Alexandra Papaioannou; Nicole Zytaruk; David Hanley; Jonathan Adachi; David Goltzman; Timothy Murray; Anthony Hodsman Journal: CMAJ Date: 2006-07-04 Impact factor: 8.262
Authors: M C Nevitt; P Chen; D P Kiel; J-Y Reginster; R K Dore; J R Zanchetta; E V Glass; J H Krege Journal: Osteoporos Int Date: 2006-08-08 Impact factor: 4.507
Authors: P Hadji; J R Zanchetta; L Russo; C P Recknor; K G Saag; F E McKiernan; S L Silverman; J Alam; R T Burge; J H Krege; M C Lakshmanan; D N Masica; B H Mitlak; J L Stock Journal: Osteoporos Int Date: 2011-12-13 Impact factor: 4.507
Authors: Kyoung Min Lee; Chin Youb Chung; Soon-Sun Kwon; Tae Gyun Kim; In Hyeok Lee; Ki Jin Jung; Jin Woo Park; Sang Young Moon; Moon Seok Park Journal: Clin Rheumatol Date: 2014-10-07 Impact factor: 2.980
Authors: A Fahrleitner-Pammer; B L Langdahl; F Marin; F Jakob; D Karras; A Barrett; Ö Ljunggren; J B Walsh; G Rajzbaum; C Barker; W F Lems Journal: Osteoporos Int Date: 2010-11-27 Impact factor: 4.507
Authors: L Johansson; H K Svensson; J Karlsson; L-E Olsson; D Mellström; M Lorentzon; D Sundh Journal: Osteoporos Int Date: 2019-06-21 Impact factor: 4.507